Processa Pharmaceuticals, Inc. (PCSA)
NASDAQ: PCSA · Real-Time Price · USD
0.2390
+0.0001 (0.04%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Processa Pharmaceuticals Employees
Processa Pharmaceuticals had 10 employees as of December 31, 2024. The number of employees decreased by 3 or -23.08% compared to the previous year.
Employees
10
Change (1Y)
-3
Growth (1Y)
-23.08%
Revenue / Employee
n/a
Profits / Employee
-$1,185,012
Market Cap
1.25M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PCSA News
- 12 days ago - Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025 - GlobeNewsWire
- 5 weeks ago - Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference - GlobeNewsWire
- 2 months ago - Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference - GlobeNewsWire
- 3 months ago - Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 3 months ago - Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 7 months ago - Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer - GlobeNewsWire
- 8 months ago - Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September - GlobeNewsWire
- 11 months ago - Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer - GlobeNewsWire